Haema_Octapharma_01_2016_Figure 01

The rationale for developing Nuwiq® (Human-cl rhFVIII) was to develop a recombinant FVIII from a human cell line that sets new standards in the treatment of patients with haemophilia.

Figure 1. The rationale for developing Nuwiq® (Human-cl rhFVIII) was to develop a recombinant FVIII from a human cell line that sets new standards in the treatment of patients with haemophilia.6,18